NCT04515979View on ClinicalTrials.gov

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2024

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Vactosertib 300 mg BID and pembrolizumab 200 mg IV

Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).

Trial Locations (1)

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

MedPacto, Inc.
All Listed Sponsors
lead

MedPacto, Inc.

INDUSTRY

NCT04515979 - Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects | Biotech Hunter | Biotech Hunter